Cargando…
Dose–Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light–Dark Test in Mice
Earlier studies have shown that combination of antibodies to S100 protein and to cannabinoid receptor type 1 in released-active form (Brizantin) may possess anxiolytic properties and decrease nicotine dependence. Released-active form of antibodies is a novel approach that permits to modify natural f...
Autores principales: | Kardash, Elena V., Ertuzun, Irina A., Khakimova, Gul'nara R., Kolyadin, Andrey N., Tarasov, Sergey A., Wagner, Stéphanie, Andriambeloson, Emile, Ivashkin, Vladimir T., Epstein, Oleg I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043939/ https://www.ncbi.nlm.nih.gov/pubmed/30013455 http://dx.doi.org/10.1177/1559325818779752 |
Ejemplares similares
-
In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form
por: Gorbunov, Evgeniy A, et al.
Publicado: (2015) -
Novel Approach to Activity Evaluation for Release-Active Forms of Anti-Interferon-Gamma Antibodies Based on Enzyme-Linked Immunoassay
por: Gavrilova, Elena S., et al.
Publicado: (2014) -
Methyllycaconitine- and scopolamine-induced cognitive dysfunction: differential reversal effect by cognition-enhancing drugs
por: Andriambeloson, Emile, et al.
Publicado: (2014) -
The use of the dynamic weight bearing test to assess the effects of acute, intramuscularly administered botulinum neurotoxin type A1 in rats
por: Cornet, Sylvie, et al.
Publicado: (2020) -
Vascular cognitive impairment: pathophysiological mechanisms, insights into structural basis, and perspectives in specific treatments
por: Parfenov, Vladimir A, et al.
Publicado: (2019)